EVOFEM BIOSCIENCES, INC.

EVFM

CIK 0001618835 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$10M
↑+34.6% +$2Mvs FY2024 (Q4)
Operating Income
$2M
↓-51.0% -$3Mvs FY2024 (Q4)
Net Income
$2M
↓-55.1% -$2Mvs FY2024 (Q4)
Gross Profit
$7M
↑+24.6% +$1Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
57/100
  • Profitability
    0ROIC -4.6% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.18 (above 1.5 = solid)
  • Leverage
    85D/E 0.30 (under 0.5 = conservative)
  • Efficiency
    55Asset Turnover 0.92x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +34.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 25.3% · trend +69.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$3K
investment in PP&E
Dividends paid (TTM)
cash returned to holders
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$166K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$20M
everything owned
Total liabilities
$90M
everything owed
Stockholders' equity
$-74M
shareholder claim
Net debt
$2M
LT debt minus cash

Recent performance · 51 quarters

Revenue↑+34.6% +$2M
$10M
Net Income
$2M
Free Cash Flow
$28K
Operating Margin
25.3%

Drill down